Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | CDK7 | P50613 | 1/20 | 0.50 |
| ▸ | CCNH | P51946 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2095604 | 0.85 | MAPT (0.39) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL7488150 | 0.85 | MAPT (0.40) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL5208376 | 0.81 | MAPT (0.54) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL7166763 | 0.81 | MAPT (0.50) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL2089837 | 0.81 | HDAC8 (0.47) | MAPTFFAR1CYP1A2CYP3A4MAPK1 | |
| SCHEMBL131765 | 0.79 | MAPT (0.46) | MAPTRAPGEF4CES2 | |
| SCHEMBL630874 | 0.79 | MEN1 (0.42) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL2925587 | 0.77 | MAPT (0.58) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL29748950 | 0.77 | MAPT (0.58) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL394991 | 0.77 | KIF11 (0.70) | MAPTMEN1KMT2AHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190330192-A1 | SUBSTITUTED AZOLYLPYRROLONES AND AZOLYLHYDANTOINS AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-10-31 | — | — | US | claimed |
| EP-3558976-A1 | SUBSTITUTED AZOLYLPYRROLONES AND AZOLYLHYDANTOINES AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | Bayer CropScience Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | claimed |
| EP-2004653-B1 | 3-SUBSTITUTED N-(ARYL- OR HETEROARYL)-PYRAZO[1,5-A]PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-12-30 | — | — | EP | claimed |
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | claimed |
| CN-101460500-A | 3-substituted N-(aryl- or heteroaryl)-pyrazo[1,5-a]pyrimidines as kinase inhibitors | NOVARTIS AG (CH) | 2009-06-17 | — | — | CN | claimed |
| EP-2004653-A1 | 3-SUBSTITUTED N-(ARYL- OR HETEROARYL)-PYRAZO[1,5-a]PYRIMIDINES AS KINASE INHIBITORS | Novartis AG (CH) | 2008-12-24 | — | — | EP | claimed |
| WO-2007113000-A1 | 3-SUBSTITUTED N-(ARYL- OR HETEROARYL)-PYRAZO[1,5-a]PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | claimed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| US-5238909-A | For preemergence or postemergence use | EASTMAN KODAK COMPANY (US) | 1993-08-24 | — | — | US | claimed |
| EP-0476760-A2 | 4-substituted isoxazole herbicides | EASTMAN KODAK COMPANY (US) | 1992-03-25 | — | — | EP | claimed |
| US-5025034-A | Thromboxane inhibitors | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1991-06-18 | — | — | US | claimed |
| US-4945106-A | Prostaglandins | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1990-07-31 | — | — | US | claimed |
| US-4159331-A | Antihypertensive 4-aminoquinolines | THE UPJOHN COMPANY (US) | 1979-06-26 | — | — | US | claimed |
| US-4032642-A | SEDATIVES, TRANQUILIZERS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1977-06-28 | — | — | US | claimed |
| US-3956296-A | ANTIINFLAMMATORY, SEDATIVES, TRANQUILIZERS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1976-05-11 | — | — | US | claimed |
| WO-2024071216-A1 | PYRAZOLE COMPOUND AND PEST CONTROL AGENT CONTAINING SAME AS ACTIVE INGREDIENT | 三井化学クロップ＆ライフソリューション株式会社 | 2024-04-04 | — | — | WO | disclosed |
| US-4085144-A | ANTIBACTERIAL | STERLING DRUG INC. (US) | 1978-04-18 | — | — | US | disclosed |
| US-4022833-A | ANTIBACTERIAL AGENTS | STERLING DRUG INC. (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | MAPT 1353/4885MEN1 1920/4885KMT2A 439/4885 |
| US-20190330192-A1 | SUBSTITUTED AZOLYLPYRROLONES AND AZOLYLHYDANTOINS AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | AGPS, AASDHPPT, HPD | MAPT 4075/4885MEN1 2887/4885KMT2A 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.